Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents
Current Hematologic Malignancy Reports, ISSN: 1558-822X, Vol: 11, Issue: 1, Page: 52-60
2016
- 6Citations
- 20Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations6
- Citation Indexes6
- CrossRef4
- Captures20
- Readers20
- 20
Review Description
The field of oncology has been transformed over the course of the last 20 years in large part due to the enhanced understanding of cellular biology and cellular signaling. The indolent natural history of chronic lymphocytic leukemia (CLL) has permitted extensive study of cancer biology and can in some ways be thought of a model for understanding and translating concepts to other diseases. By systematically probing the biology of CLL cells and working out in stepwise fashion the transduction of signals from the surface immunoglobulin to nuclear transcription factors, investigators have paved the way for rational targeting of therapies at natural vulnerabilities that mimic oncogene addiction. These key targets include Bruton’s tyrosine kinase (BTK), phosphatidylinositol 3-kinase (PI3K), Src, Bcl2, and cyclin-dependent kinases (CDKs). In this review, we will consider these proteins and describe the current and future molecules designed to target them in CLL.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84961210957&origin=inward; http://dx.doi.org/10.1007/s11899-016-0299-0; http://www.ncbi.nlm.nih.gov/pubmed/26893063; http://link.springer.com/10.1007/s11899-016-0299-0; https://dx.doi.org/10.1007/s11899-016-0299-0; https://link.springer.com/article/10.1007/s11899-016-0299-0; http://link.springer.com/content/pdf/10.1007/s11899-016-0299-0; https://link.springer.com/content/pdf/10.1007/s11899-016-0299-0.pdf; http://link.springer.com/content/pdf/10.1007/s11899-016-0299-0.pdf; https://link.springer.com/content/pdf/10.1007%2Fs11899-016-0299-0.pdf; http://link.springer.com/article/10.1007%2Fs11899-016-0299-0; http://link.springer.com/article/10.1007/s11899-016-0299-0/fulltext.html
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know